



## Press Release

# Cipla appoints Ms.Punita Lal and Dr. Nachiket Mor as Independent Directors on its Board

**India, Mumbai, 13<sup>th</sup> November 2014:** Cipla Limited (“Cipla”), a global Indian pharmaceutical company is delighted to announce the appointment of Ms. Punita Lal and Dr. Nachiket Mor as the independent directors on its board effective 13<sup>th</sup> November 2014.

**Ms. Punita Lal** is a graduate in Economics from St. Stephens College, New Delhi and PGDM from the Indian Institute of Management, Kolkata. Post a successful executive career, Ms Lal is now focused on advisory roles. She sits on the Board of CEAT Limited as an independent director, is an independent strategy and marketing consultant, and is also affiliated with a global firm as a leadership coach.

In her last role, Ms. Punita Lal was the CEO of NourishCo, a JV between PepsiCo and Tatas, where she was responsible for establishing and growing the business, and launching two beverage innovations in the first year of JV operations. An FMCG specialist, Ms. Lal worked in different senior marketing positions with Coca-Cola in China and the Far East until 2002. She then joined PepsiCo as the Head of Marketing for their South Asia business unit, where she was responsible for devising marketing and portfolio strategy across PepsiCo’s beverage brands in South Asia, a USD 1 billion business. Ms. Lal began her career in the advertising industry where she worked for leading advertising firms – Lintas and J Walter Thompson.

Welcoming her appointment as an independent director, **Dr. Y K Hamied, Chairman, Cipla Limited** said: “We believe that Ms. Lal’s proven experience in a marketing and advisory role will add value to our Cipla board.”

**Ms. Punita Lal** said: "I have long admired Cipla as a company that bridges the frontiers of science and humanity, and look forward to being part of this continuing journey.”

**Dr. Nachiket Mor** is a Yale World Fellow; has a Ph.D. in Economics from the Graduate School of Arts and Sciences at the University of Pennsylvania, with a specialization in Finance from the Wharton School; a MBA in Finance from the Indian Institute of Management, Ahmedabad; and a BS in Physics from the Mumbai University.

Dr. Mor is currently on the Board of CRISIL Limited as an Independent Director and also serves on the Boards of Reserve Bank of India, IKP Trust and CARE India in a similar capacity.

Dr. Mor worked with ICICI from 1987 to 2007 and was a member of its Board of Directors from 2001 to 2007. From 2007 to 2011, he served as the founding President of ICICI Foundation and during this period was also the Chair of the Governing Council of IFMR Trust and Board Chair of Financial Inclusion Network & Operations (FINO) Limited. In the past he has also served as a Board Member of Wipro for five years and Board Chair of the Fixed Income Money Market and Derivatives Association of India for two years.

Welcoming his appointment, **Dr. Y K Hamied, Chairman, Cipla Limited** said: “Dr. Nachiket Mor is a pioneer in the banking and financial industry. His experience and passion in the areas of financial access and healthcare will be extremely valuable and a great asset to the Cipla board.”

**Dr. Mor** said “Cipla’s global contribution to the cause of reducing the burden of HIV/AIDs and its efforts to make low-cost medicines universally available are both well known. As a member of their Board I look forward to learning more about the industry and Cipla’s role in it.”

### **About Cipla Limited**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2013-14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UK MHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

### **Media Contact:**

Charlotte Chunawala  
Corporate Communications  
Mob: +91 7506257377  
Email: [charlotte.chunawala@cipla.com](mailto:charlotte.chunawala@cipla.com)

Jaisingh Balakrishnan  
Corporate Communications  
Mob: +91 9833836185  
Email: [jaisingh.krishnan@cipla.com](mailto:jaisingh.krishnan@cipla.com)